Experimental Alzheimer’s Drug Clears Initial Safety Trials for Accelerated Development
An experimental drug, KCL-286, has cleared initial human safety trials, offering a potential multi-target therapy for Alzheimer’s disease by addressing DNA…

Researchers have identified an experimental small-molecule drug, KCL-286, capable of addressing multiple biological drivers of Alzheimer’s disease. The compound functions by activating the retinoic acid pathway, which facilitates DNA repair and reduces neuroinflammation.
Unlike current therapies that primarily target protein accumulation, this drug addresses cellular damage occurring in the early stages of disease progression. The treatment is orally bioavailable, potentially simplifying administration compared to existing injectable or infusion-based protocols.
KCL-286 has already completed Phase 1 human safety and tolerability trials during its prior development for spinal cord injury. This regulatory milestone is expected to significantly reduce the timeline for subsequent clinical efficacy testing. While the drug has demonstrated success in animal models, its clinical effectiveness in human Alzheimer’s patients remains to be established.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- Children with higher ultra-processed intake show stronger reward signals
- Avocado-mango diet linked to 6.7% vessel function in prediabetes
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Europe faces attribution gap after 16 cyber, physical incidents

